Biologic Disease-Modifying Antirheumatic Drugs Do Not Increase Risk for Prosthetic Joint Infection in Setting of Total Knee Arthroplasty

被引:1
作者
Bains, Sandeep S. [1 ]
Chen, Zhongming [1 ]
Sax, Oliver C. [1 ]
Salib, Christopher G. [1 ]
Paulson, Ambika E. [1 ]
Delanois, Ronald E. [1 ,2 ]
机构
[1] Sinai Hosp Baltimore, Rubin Inst Adv Orthoped, LifeBridge Hlth, Baltimore, MD USA
[2] Sinai Hosp Baltimore, Rubin Inst Adv Orthoped, 2401 West Belvedere Ave, Baltimore, MD 21215 USA
关键词
DMARDs; TKA; biologics; nonbiologics; RHEUMATOID-ARTHRITIS; ORTHOPEDIC-SURGERY; TOTAL HIP; COMPLICATIONS;
D O I
10.1055/s-0042-1760389
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Over 25% of patients with rheumatoid arthritis (RA) are expected to undergo a joint replacement during their lifetime. Current practice guidelines recommend withholding biologic therapy 1 week prior to total hip arthroplasty, given its immunosuppressive effects. Most patients are on a regimen including biologic and nonbiologic therapy; however, the individual influences of these therapies are not well understood in the setting of total knee arthroplasty (TKA). Therefore, we sought to compare biologic, nonbiologic, and recipients of both types of therapy in patients with RA undergoing TKA. We specifically assessed (1) medical complications at 90 days; (2) surgical complications up to 1 year; and (3) independent risk factors for prosthetic joint infections (PJIs).A retrospective review was conducted using a national, all-payer database for patients undergoing primary TKA from January 2010 to April 2020 ( n = 1.97 million). Patients diagnosed with RA were then separated into at least 1-year users of biologic ( n = 3,092), nonbiologic (28,299), or dual ( n = 10,949) therapy. Bivariate analyses were utilized to assess for 90-day medical and up to 1-year surgical outcomes. Additionally, multivariate regression models were utilized to assess for independent risk factors.The incidence and odds ratio for medical/surgical outcomes were equivocal among the biologic, nonbiologic, and recipients receiving both types of therapy ( p > 0.061). No differences were observed between the type of therapy as additional risk factors for infection ( p > 0.505). However, glucocorticoids at 90 days and alcohol abuse, diabetes mellitus, obesity, as well as tobacco use were identified as additional risk factors for PJI( p < 0.036).No appreciable differences in medical or surgical outcomes were associated with the independent use of biologic, nonbiologic, or recipients of both types of therapy in patients with RA. Additionally, alcohol abuse, diabetes mellitus, glucocorticoids, obesity, and tobacco use conferred an increased risk of PJI. These results can serve as an adjunct to current practice guidelines.
引用
收藏
页码:121 / 127
页数:7
相关论文
共 15 条
  • [1] High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis
    Au, Karen
    Reed, George
    Curtis, Jeffrey R.
    Kremer, Joel M.
    Greenberg, Jeffrey D.
    Strand, Vibeke
    Furst, Daniel E.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (05) : 785 - 791
  • [2] Incidence and Risk Factors of Prosthetic Joint Infection After Total Hip or Knee Replacement in Patients With Rheumatoid Arthritis
    Bongartz, Tim
    Halligan, Christine S.
    Osmon, Douglas R.
    Reinalda, Megan S.
    Bamlet, William R.
    Crowson, Cynthia S.
    Hanssen, Arlen D.
    Matteson, Eric L.
    [J]. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2008, 59 (12): : 1713 - 1720
  • [3] Perioperative Continuation of Biologic Medications Increases Odds of Periprosthetic Joint Infection in Patients With Inflammatory Arthropathy
    Carlson, Victor R.
    Anderson, Lucas A.
    Lu, Chao-Chin
    Sauer, Brian C.
    Blackburn, Brenna E.
    Gililland, Jeremy M.
    [J]. JOURNAL OF ARTHROPLASTY, 2021, 36 (07) : 2546 - 2550
  • [4] 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty
    Goodman, Susan M.
    Springer, Bryan
    Guyatt, Gordon
    Abdel, Matthew P.
    Dasa, Vinod
    George, Michael
    Gewurz-Singer, Ora
    Giles, Jon T.
    Johnson, Beverly
    Lee, Steve
    Mandl, Lisa A.
    Mont, Michael A.
    Sculco, Peter
    Sporer, Scott
    Stryker, Louis
    Turgunbaev, Marat
    Brause, Barry
    Chen, Antonia F.
    Gililland, Jeremy
    Goodman, Mark
    Hurley-Rosenblatt, Arlene
    Kirou, Kyriakos
    Losina, Elena
    MacKenzie, Ronald
    Michaud, Kaleb
    Mikuls, Ted
    Russell, Linda
    Sah, Alexander
    Miller, Amy S.
    Singh, Jasvinder A.
    Yates, Adolph
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69 (08) : 1538 - 1551
  • [5] Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery
    Grennan, DM
    Gray, J
    Loudon, J
    Fear, S
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 (03) : 214 - 217
  • [6] Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases
    Grijalva, Carlos G.
    Chen, Lang
    Delzell, Elizabeth
    Baddley, John W.
    Beukelman, Timothy
    Winthrop, Kevin L.
    Griffin, Marie R.
    Herrinton, Lisa J.
    Liu, Liyan
    Ouellet-Hellstrom, Rita
    Patkar, Nivedita M.
    Solomon, Daniel H.
    Lewis, James D.
    Xie, Fenglong
    Saag, Kenneth G.
    Curtis, Jeffrey R.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 306 (21): : 2331 - 2339
  • [7] Orthopaedic surgery in patients with rheumatoid arthritis over 20 years: prevalence and predictive factors of large joint replacement
    Kapetanovic, M. C.
    Lindqvist, E.
    Saxne, T.
    Eberhardt, K.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (10) : 1412 - 1416
  • [8] Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-α blockers: perioperative interruption of tumour necrosis factor-α blockers decreases complications?
    Kawakami, Kosei
    Ikari, Katsunori
    Kawamura, Koichiro
    Tsukahara, So
    Iwamoto, Takuji
    Yano, Koichiro
    Sakuma, Yu
    Tokita, Asami
    Momohara, Shigeki
    [J]. RHEUMATOLOGY, 2010, 49 (02) : 341 - 347
  • [9] Perioperative complications in elective surgery in patients with rheumatoid arthritis treated with biologics
    Kubota, Ayako
    Nakamura, Takashi
    Miyazaki, Yoshiyasu
    Sekiguchi, Masayuki
    Suguro, Toru
    [J]. MODERN RHEUMATOLOGY, 2012, 22 (06) : 844 - 848
  • [10] Massardo L, 2002, J RHEUMATOL, V29, P52